Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 121

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 121
---
  Includes interest income and other expenses. 

136

The following presents segment revenue and long lived assets by geographic location, along with major collaborator information.Revenue by location is as follows: 

        December 31,

        2024

        2023

        (in thousands)

        Switzerland
         
        $
        50,888

        $
        14,545

        United States

        2,589

        26,115

        Japan

        —

        10,473

        Total revenue
         
        $
        53,477

        $
        51,133

      The Company’s property and equipment, net by country of domicile (Canada) and its subsidiary in the United States are as follows: 

        December 31,

        2024

        2023

        (in thousands)

        Canada
         
        $
        2,143

        $
        3,469

        United States

        151

        746

        Total property and equipment, net
         
        $
        2,294

        $
        4,215

      The Company’s right-of-use assets by country of domicile (Canada) and its subsidiary in the United States are as follows:  

        December 31,

        2024

        2023

        (in thousands)

        Canada
         
        $
        891

        $
        2,376

        United States

        1,033

        950

        Total right-of-use assets, net
         
        $
        1,924

        $
        3,326

      Major Customers

The Company had one customer (a major collaborator) that represents more than 10% of total revenue. The amount of revenue derived from this customer for the year ended December 31, 2024, was $50.9 million. 

22. Subsequent EventsOn January 9, 2025, the Company announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-3467 and RP-1664. The Company also announced its intention to seek partnering opportunities across its portfolio, including lunresertib and camonsertib prior to the start of any pivotal development. Effective February 24, 2025, the Company implemented a reduction of its workforce by approximately 75% to extend